肠易激综合征伴便秘患者安慰剂应答的相关因素
该研究对一项为期12周、随机双盲、3期试验中接受安慰剂的599例肠易激综合征伴便秘女性患者进行回顾性分析,以腹痛应答为主要终点,采用后退消除法结合自举法识别与安慰剂应答相关的因素。结果显示29.0%的患者出现腹痛应答,基线腹痛变异、基线最大疼痛严重程度及第2周或第3周安慰剂应答与应答相关,基线完全自发排便次数和最终基线疼痛评分与无应答相关。
要点
- 599例肠易激综合征伴便秘女性接受安慰剂,29.0%出现腹痛应答。
- 基线腹痛变异(OR 1.71)、基线最大疼痛严重程度(OR 1.34)与安慰剂应答相关。
- 第2周(OR 2.23)或第3周(OR 3.69)安慰剂应答与后续应答相关。
核心结论
- 在肠易激综合征伴便秘女性中,基线疼痛症状变异、基线症状严重程度及腹痛早期改善与安慰剂应答相关,这些发现对临床试验设计有重要意义。
研究设计与样本
- 对一项为期12周、随机双盲、3期试验中接受安慰剂的599例肠易激综合征伴便秘女性患者进行回顾性分析。
主要发现
- 安慰剂组中29.0%的患者出现腹痛应答,定义为12周研究期内至少6周腹痛较基线改善≥30%。
- 与安慰剂应答相关的因素包括基线腹痛变异(OR 1.71)、基线最大疼痛严重程度(OR 1.34)、研究第2周安慰剂应答(OR 2.23)或第3周安慰剂应答(OR 3.69)。
- 与安慰剂无应答相关的因素包括基线完全自发排便次数(OR 0.73;P = .019)和最终基线疼痛评分(OR 0.73;P < .001)。
关键数值与推荐
- 腹痛应答定义为12周研究期内至少6周腹痛较基线改善≥30%。
- 采用后退消除回归结合自举法识别与安慰剂应答相关的因素。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: A high proportion of patients with irritable bowel syndrome (IBS) respond to placebo in clinical trials (estimated at about 40%). We aimed to identify factors that contribute to the high placebo response rate using data from a placebo-controlled trial of patients with IBS. METHODS: We performed a retrospective analysis of 599 women with IBS with constipation who were in the placebo group of a 12-week, randomized, double-blind, phase 3 trial of the experimental medication renzapride. Primary analyses evaluated frequency of abdominal pain in patients who received placebo, defined as ≥30% pain improvement from baseline for ≥6 of the 12 study weeks. We performed backward elimination regression with bootstrapping to identify factors associated with response to placebo. RESULTS: In the placebo group, 29.0% of the patients had an abdominal pain response. Factors associated with a response to placebo were baseline variation in abdominal pain (odds ratio [OR], 1.71), maximum baseline pain severity (OR, 1.34), and placebo response in study week 2 (OR, 2.23) or week 3 (OR, 3.69). Factors associated with lack of response to placebo were number of baseline complete spontaneous bowel movements (OR, 0.73; P = .019) and final baseline pain ratings (OR, 0.73; P < .001). CONCLUSIONS: We identified factors associated with a response in abdominal pain to placebo using original data from an IBS clinical trial. Baseline factors associated with the placebo response in women with IBS and constipation included variation in baseline pain symptoms, severity of baseline symptoms, and early improvement of abdominal pain. These findings have significant implications for clinical trial design.
引用
- Ballou S, Beath A, Kaptchuk TJ, et al. Factors Associated With Response to Placebo in Patients With Irritable Bowel Syndrome and Constipation. Clin Gastroenterol Hepatol. 2018. PMID: 29654913. doi:10.1016/j.cgh.2018.04.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。